BioSpace News Archive

“Defensins are conceptually ideal for defense against different viral infections” WAKEFIELD, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today the Company is exploring its lead defensin mimetic drug candidate, Brilacidin, as a potential novel coronavirus treatment. Over the last few weeks, the Company has received inquiries asking about Brilacidin’s potential to treat the Coronavirus g

THOROLD, ON , Feb. 18, 2020 /PRNewswire/ - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acid and protein stabilization and purification, today announced that they are offering a number of products to the scientific and medical community to support the study of the 2019 Novel Coronavi

Feb. 18, 2020 16:56 UTC Respondents Recognize Contribution to Medical and Health Breakthroughs; Cite Need for More People to Register for Organ Donations PHILADELPHIA--( BUSINESS WIRE )-- A strong majority of Americans agree that organ and tissue donation for research contributes to health and medical breakthroughs and acknowledge significant shortfalls for donation. This is according to a new survey released today commissioned by Research!America in partnership with

Study Finds Biological Process that Helps Underdeveloped Lungs Fight Infections

Revolution Medicines, Inc. announced the closing of its initial public offering of 16,100,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares of common stock, at a public offering price of $17.00 per share.

Catalyst Biosciences, Inc. announced the closing of an underwritten public offering of 5,307,692 shares of its common stock, offered at a price of $6.50 per share to the public, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 692,307 shares of its common stock.

Kewaunee Scientific Corporation announced that the Company plans to release its third quarter fiscal year 2020 financial results on Tuesday, March 3, 2020 after the close of trading.

Viracta Therapeutics, Inc. announced that Ivor Royston, M.D., the Company’s President and CEO, will present an overview of Viracta’s approach in treating patients with Epstein-Barr Virus -associated malignancies and data from the ongoing Phase 2 clinical trial in lymphoma.

Dicerna Pharmaceuticals, Inc. announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at two upcoming investor conferences

AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced fourth quarter 2019 and full year 2019 financial results.